Steris Projects Stronger Profit Growth for 2027

Steris forecast stronger earnings growth for fiscal 2027 on Monday, signaling continued confidence in demand for medical sterilization and infection-prevention services.

The company expects adjusted earnings per share between $11.10 and $11.30 for fiscal 2027, slightly above analyst expectations.

Steris also projected annual revenue growth of 7% to 8%, reflecting continued momentum in healthcare procedures and laboratory activity.

The outlook highlights the resilience of healthcare equipment demand despite broader economic uncertainty and elevated operating costs across many industries.

Hospital Procedure Volumes Continue Supporting Growth

Steris benefited from increasing medical procedure volumes during its latest quarter.

Hospitals and healthcare providers continue performing higher numbers of elective and non-elective procedures, supporting demand for sterilization systems, surgical equipment, and infection-control products.

The company reported quarterly revenue of $1.6 billion for the period ended March 31, representing a 7% increase from the prior year and slightly above analyst estimates.

Its diversified customer base across hospitals, laboratories, pharmaceutical companies, and healthcare systems also helped support stable growth.

Healthcare Division Remains Core Driver

Steris’ largest business segment, Healthcare, generated strong results during the quarter.

Revenue from the Healthcare division increased 7% to $1.14 billion as hospitals continued investing in sterilization products and surgical workflow systems.

The company’s Applied Sterilization Technologies division also posted growth, with revenue rising 6% to $289.2 million.

Meanwhile, the Life Sciences segment delivered the strongest percentage growth, climbing 9% to $162.9 million as pharmaceutical and laboratory demand remained healthy.

The broad-based expansion across all major business lines reinforced investor confidence in the company’s long-term outlook.

Earnings Slightly Miss Expectations

Despite the strong revenue growth and optimistic guidance, Steris narrowly missed Wall Street profit expectations for the fourth quarter.

The company reported adjusted earnings of $2.83 per share, slightly below analyst estimates of $2.85 per share.

However, investors appeared more focused on the company’s forward guidance and continued revenue momentum rather than the modest quarterly earnings miss.

The healthcare equipment sector has remained relatively defensive during periods of economic uncertainty due to stable demand for medical services and hospital infrastructure.

Share Buyback Adds Investor Support

Steris also announced authorization for a new $1 billion share repurchase program.

Share repurchase plans are often viewed positively by investors because they can reduce the number of outstanding shares and improve earnings per share over time.

The buyback announcement reflects management’s confidence in the company’s cash flow generation and long-term growth strategy.

Medical Equipment Industry Remains Resilient

Healthcare equipment manufacturers have generally benefited from stable healthcare spending and aging populations worldwide.

Companies involved in infection prevention, sterilization, and surgical technologies continue seeing relatively consistent demand even during periods of economic volatility.

Steris’ latest forecast suggests hospitals and healthcare systems remain willing to invest in critical infrastructure and patient safety technologies despite inflationary pressures and rising operating costs.

The company’s performance also highlights how healthcare-related industries continue providing investors with relatively stable growth compared to more cyclical sectors.